عنوان مقاله [English]
Introduction: Ovarian cancer is often diagnosed at an advanced stage and evaluation of the various factors for early diagnosis of this cancer is highly valuable. This study was performed with the aim to evaluate the expression of HER-2/neu and P16 in epithelial ovarian tumors and its correlation with clinicopathologic variables.
Methods: This descriptive-analytic and cross-sectional study was performed on 50 paraffin blocks of epithelial ovarian tumors obtained from the archives of pathology department of Mashhad Omid and Ghaem Hospitals during 2007 to 2013. After cutting the blocks, appropriate slides were prepared and immunohistochemical expression pattern of them, the slides were interpreted by an experienced pathologist. The study variables included patient's age, disease stage, histological type of tumor, expression or non-expression of HER2-neu and P16 and survival of patients. The data related to the patients were extracted from the files available in department of Oncology, Ghaem Hospital. Data was analyzed using SPSS software (version 11.5) and Kruskal-Wallis, Mann-Whitney, T-test and chi-square test. PResults: In this study, most common epithelial ovarian tumor was serous adenocarcinoma (64%). P16 was expressed in 32% of tumors, and its expression was associated with disease stage and overall survival of the patients (P = 0.001, P = 0.04). HER-2 was expressed in 28% of cases. Its expression was associated with histological type of tumor (P = 0.03). But, no relation was observed between its expression and overall survival of the patients (P = 0.07) and disease stage (P = 0.70).
Conclusion: With regard to significant relation of P16 expression with disease stage and overall survival of the patients, P16 expression is considered as a predictive factor of overall survival and disease stage. While, expression of HER-2 cannot be used as a prognostic factor of overall survival.
2. Rock JA, Jones HW. TeLinde's Operative Gynecology. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p.1487-96.
3. Berton-Rigaud D1, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer 2014;24(9 Suppl 3):S55-60.
4. Harter P1, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors). Int J Gynecol Cancer 2014;24(9 Suppl 3):S5-8.
5. Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol 2014; 135(2):223-30
6. Tangjitgamol S, Tanvanich S, Srijaipracharoen S, Manusirivithaya S. Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer. Histol Histopathol 2013;28(6):787-94.
7. Mamani-Cancino AD, Veloz-Martínez MG, Casasola-Busteros I, Moctezuma-Meza C, García-Cebada JM. [Frequency factor Her-2/neu overexpression in patients with breast cancer]. Ginecol Obstet Mex 2014;82(6):369-76.(Spanish).
8. Wang Y1, Zhang XR, Fu J, Tan W, Zhang W. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi.2004;26(6):369-72.(Chinese).
9. Zahir ST, Tafti HF, Rahmani K. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma. Asian Pac J Cancer Prev 2014;15(15):6425-8.
10. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98(1):66-73.
11. Wang Y1, Wang D, Ren M. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis. Tumour Biol 2014;35(1):33-8.
12. Bhagat R1, Kumar SS, Vaderhobli S, Premalata CS, Pallavi VR, Ramesh G, et al. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma. Tumour Biol 2014;35(9):9069-78.
13. Giordano G1, Azzoni C, D'Adda T, Rocco A, Gnetti L, Froio E, et al. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Pathol Res Pract 2008;204(3):163-74.
14. Khouja MH1, Baekelandt M, Nesland JM, Holm R. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 2007;26(4):418-25.
15. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997;74(1):57-63.
16. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13(1):8-15.
17. 17-Surowiak P1, Materna V, Maciejczyk A, Pudelko M, Suchocki S, Kedzia W, et al. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol Histopathol 2008;23(5):531-8.
18. O’Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumor. Histopathology 2007; 50: 773-9.
19. Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F. the AGO-OVAR. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br. J. Cancer 2007; 96: 306-13.
20. Coronado Martín PJ1, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc) 2007;128(1):1-6.(Spanish).
21. Wu Y1, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004;95(3):570-5.
22. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR. p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 1997;65(2):218-24.
23. Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 2004;95(1):89-94.
24. Steffensen KD1, Waldstrøm M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer 2011;21(6):1040-7.
25. Hoopmann M1, Sachse K, Valter MM, Becker M, Neumann R, Ortmann M, et al. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care (Engl) 2010;19(6):809-15.
26. Ferrero A1, Dompè D, Ravarino N, Ramella A, Fuso L, Maggiorotto F, et al. Angiogenesis and molecular markers in advanced epithelial ovarian cancer: a retrospective study. Gynecol Oncol 2011;123(2):301-7.
27- Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005;68(2-3):154-61